{"id":"pramipexole-mirapex","safety":{"commonSideEffects":[{"rate":"26–62%","effect":"Nausea"},{"rate":"25–53%","effect":"Dizziness"},{"rate":"27–41%","effect":"Somnolence"},{"rate":"17–27%","effect":"Insomnia"},{"rate":"5–17%","effect":"Hallucinations"},{"rate":"5–30%","effect":"Orthostatic hypotension"},{"rate":"5–10%","effect":"Impulse control disorders"}]},"_chembl":{"chemblId":"CHEMBL3143955","moleculeType":"Small molecule","molecularWeight":"284.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pramipexole selectively binds to dopamine receptors, particularly D2 and D3 subtypes, in brain regions affected by neurodegeneration. By mimicking dopamine's action, it compensates for the loss of dopamine-producing neurons, thereby alleviating motor symptoms in Parkinson's disease and reducing the sensory and motor symptoms of restless legs syndrome.","oneSentence":"Pramipexole is a dopamine agonist that stimulates D2 and D3 dopamine receptors in the brain to restore dopamine signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:01.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT05003648","phase":"PHASE4","title":"Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-04-01","conditions":"Adrenoleukodystrophy, Restless Legs Syndrome","enrollment":24},{"nctId":"NCT07240675","phase":"PHASE1","title":"Single-dose,First-in-human of KLA478","status":"RECRUITING","sponsor":"Hunan Kelun Pharmaceutical Co., Ltd.","startDate":"2025-11-26","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT07382960","phase":"","title":"Pramipexole and the Risk of Serious Adverse Events","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-01-01","conditions":"Older Adults (65 Years and Older), Chronic Kidney Disease (CKD)","enrollment":1100},{"nctId":"NCT06705478","phase":"PHASE2","title":"Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-15","conditions":"Major Depressive Disorder, Mild Neurocognitive Disorder, HIV","enrollment":186},{"nctId":"NCT02220309","phase":"","title":"Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-08-11","conditions":"Anxiety, Depression","enrollment":167},{"nctId":"NCT05763121","phase":"PHASE3","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.","status":"TERMINATED","sponsor":"Areteia Therapeutics","startDate":"2023-01-30","conditions":"Eosinophilic Asthma, Asthma; Eosinophilic, Asthma","enrollment":1061},{"nctId":"NCT06388889","phase":"PHASE3","title":"Phase III Long-Term Extension Study With Dexpramipexole","status":"TERMINATED","sponsor":"Areteia Therapeutics","startDate":"2024-06-12","conditions":"Eosinophilic Asthma","enrollment":509},{"nctId":"NCT05813288","phase":"PHASE3","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)","status":"TERMINATED","sponsor":"Areteia Therapeutics","startDate":"2023-03-27","conditions":"Eosinophilic Asthma, Asthma; Eosinophilic, Asthma","enrollment":654},{"nctId":"NCT04121091","phase":"PHASE2","title":"Pramipexole to Target \"Anhedonic Depression\"","status":"COMPLETED","sponsor":"Region Skane","startDate":"2019-10-04","conditions":"Depression, Bipolar, Depression, Unipolar, Dysthymia","enrollment":13},{"nctId":"NCT04759703","phase":"PHASE2, PHASE3","title":"Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2022-01-24","conditions":"Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder","enrollment":75},{"nctId":"NCT06580041","phase":"PHASE4","title":"Precision Care for Major Depressive Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2024-11-12","conditions":"Major Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":150},{"nctId":"NCT05748600","phase":"PHASE3","title":"A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Areteia Therapeutics","startDate":"2023-01-30","conditions":"Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack","enrollment":600},{"nctId":"NCT06457204","phase":"PHASE1","title":"A Study in Healthy People to Compare Two Different Sifrol® Tablets","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-07-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT05355337","phase":"PHASE3","title":"Pramipexole for Anhedonic Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2023-02-08","conditions":"Psychiatric Disorders Mood, Anhedonia, Depression","enrollment":120},{"nctId":"NCT05825235","phase":"PHASE3","title":"Long-term Efficacy of Pramipexole in Anhedonic Depression","status":"RECRUITING","sponsor":"Region Skane","startDate":"2023-04-21","conditions":"Anhedonia, Depression","enrollment":80},{"nctId":"NCT07022405","phase":"PHASE2","title":"Stratified Pharmacological Approaches for Regulating Circuit-Level Effects","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-08","conditions":"Depression - Major Depressive Disorder","enrollment":60},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT06533553","phase":"PHASE2","title":"A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Areteia Therapeutics","startDate":"2024-07-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30},{"nctId":"NCT06269146","phase":"PHASE2","title":"Pramipexole to Enhance Social Connections","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-05-13","conditions":"Anxiety Disorders, Anxiety, Depression","enrollment":108},{"nctId":"NCT06611592","phase":"PHASE2","title":"Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)","status":"RECRUITING","sponsor":"Clinical Academic Center (2CA-Braga)","startDate":"2024-08-20","conditions":"Obsessive-Compulsive Disorder","enrollment":48},{"nctId":"NCT03842709","phase":"EARLY_PHASE1","title":"Non-Opioid Pramipexole and Pain","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":13},{"nctId":"NCT05401019","phase":"PHASE2","title":"Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)","status":"WITHDRAWN","sponsor":"Clinical Academic Center (2CA-Braga)","startDate":"2022-06","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT03683225","phase":"PHASE2","title":"A Study to Evaluate in Patients With Parkinsonian Type Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chase Therapeutics Corporation","startDate":"2019-04-01","conditions":"Idiopathic Parkinson Disease","enrollment":24},{"nctId":"NCT03642964","phase":"PHASE2","title":"A Study in Patients With Major Depressive Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chase Therapeutics Corporation","startDate":"2018-09-10","conditions":"Major Depressive Disorder (MDD)","enrollment":24},{"nctId":"NCT00349310","phase":"","title":"Profile of Depressive Symptoms in Parkinsons Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04-01","conditions":"Parkinson Disease, Depression","enrollment":1018},{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT04249544","phase":"PHASE1","title":"Social Decision Making in Parkinson's Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-03","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT04936126","phase":"PHASE4","title":"Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2021-08-07","conditions":"Treatment Resistant Depression","enrollment":150},{"nctId":"NCT03786614","phase":"NA","title":"Antidepressant Discontinuation in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"University of Louisville","startDate":"2019-06-20","conditions":"Treatment Resistant Depression","enrollment":30},{"nctId":"NCT04046939","phase":"PHASE2","title":"Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2019-08-15","conditions":"Eosinophilic Asthma, Asthma","enrollment":534},{"nctId":"NCT01968460","phase":"PHASE2, PHASE3","title":"Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Pharma Two B Ltd.","startDate":"2013-12","conditions":"Parkinson's Disease","enrollment":149},{"nctId":"NCT04275492","phase":"NA","title":"Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-07-24","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT03329508","phase":"PHASE3","title":"A Phase 3 Study With P2B001 in Subjects With Early Parkinson's","status":"COMPLETED","sponsor":"Pharma Two B Ltd.","startDate":"2018-01-19","conditions":"Parkinson Disease, Early Parkinson's Disease","enrollment":544},{"nctId":"NCT04160520","phase":"PHASE1, PHASE2","title":"Pramipexole and Morphine for Renal Colic","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2019-10-28","conditions":"Renal Colic","enrollment":19},{"nctId":"NCT03430596","phase":"EARLY_PHASE1","title":"a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-05-01","conditions":"Extrapyramidal Syndrome","enrollment":50},{"nctId":"NCT01622088","phase":"PHASE3","title":"Phase 3 Extension Study of Dexpramipexole in ALS","status":"TERMINATED","sponsor":"Knopp Biosciences","startDate":"2012-06","conditions":"Amyotrophic Lateral Sclerosis","enrollment":616},{"nctId":"NCT03817554","phase":"PHASE4","title":"Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients","status":"TERMINATED","sponsor":"Dong Jie","startDate":"2019-07-01","conditions":"Restless Legs Syndrome","enrollment":21},{"nctId":"NCT01388478","phase":"PHASE2","title":"Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2011-07","conditions":"Alzheimer's Disease","enrollment":20},{"nctId":"NCT00931944","phase":"PHASE2","title":"Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2009-07","conditions":"Amyotrophic Lateral Sclerosis","enrollment":74},{"nctId":"NCT00647296","phase":"PHASE2","title":"Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2008-04-09","conditions":"Amyotrophic Lateral Sclerosis","enrollment":194},{"nctId":"NCT01424163","phase":"PHASE1","title":"Dexpramipexole Japanese PK Study","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2011-08","conditions":"Amyotrophic Lateral Sclerosis","enrollment":57},{"nctId":"NCT01281189","phase":"PHASE3","title":"Phase 3 Study of Dexpramipexole in ALS","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2011-03","conditions":"Amyotrophic Lateral Sclerosis","enrollment":942},{"nctId":"NCT02217332","phase":"PHASE2","title":"Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2014-08","conditions":"Chronic Sinusitis With Nasal Polyps and Eosinophilia","enrollment":20},{"nctId":"NCT03845387","phase":"PHASE2","title":"A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2019-02-26","conditions":"Parkinson Disease","enrollment":74},{"nctId":"NCT03521635","phase":"PHASE4","title":"The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-07-03","conditions":"Parkinson Disease","enrollment":98},{"nctId":"NCT00991276","phase":"PHASE3","title":"Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-12","conditions":"Restless Legs Syndrome","enrollment":85},{"nctId":"NCT00537017","phase":"PHASE2","title":"Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-23","conditions":"Parkinson Disease, Neurodegenerative Diseases, Central Nervous System Diseases","enrollment":140},{"nctId":"NCT00806026","phase":"PHASE3","title":"Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-12","conditions":"Idiopathic Restless Legs Syndrome","enrollment":731},{"nctId":"NCT03681509","phase":"NA","title":"Pramipexole and Emotional Processing","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-09-01","conditions":"Emotions, Motivation, Reward","enrollment":43},{"nctId":"NCT02397837","phase":"PHASE4","title":"Targeting Cognition in Bipolar Disorder With Pramipexole","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-10","conditions":"Bipolar Disorder","enrollment":103},{"nctId":"NCT03765138","phase":"PHASE3","title":"Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression","status":"TERMINATED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2019-02-19","conditions":"PTSD, MDD","enrollment":1},{"nctId":"NCT02033369","phase":"PHASE4","title":"Imaging Dopamine Release in Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02","conditions":"Major Depressive Disorder","enrollment":52},{"nctId":"NCT03977441","phase":"PHASE4","title":"the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2019-07","conditions":"Parkinson Disease, Depression, Sleep Disorders","enrollment":240},{"nctId":"NCT00406029","phase":"PHASE2","title":"Dyskinesia in Parkinson's Disease (Study P04501)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11-20","conditions":"Parkinson Disease, Movement Disorders, Central Nervous System Diseases","enrollment":253},{"nctId":"NCT01733199","phase":"PHASE4","title":"Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-10","conditions":"Parkinson's Disease, Secondary Behavioural Addiction","enrollment":225},{"nctId":"NCT02101138","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-14","conditions":"Hypereosinophilic Syndrome","enrollment":15},{"nctId":"NCT01673724","phase":"PHASE4","title":"Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-02","conditions":"Parkinson's Disease","enrollment":121},{"nctId":"NCT00282152","phase":"NA","title":"Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2006-03","conditions":"Parkinson's Disease","enrollment":37},{"nctId":"NCT01066897","phase":"PHASE4","title":"Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-02","conditions":"Depression","enrollment":16},{"nctId":"NCT01441284","phase":"PHASE3","title":"Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor","status":"WITHDRAWN","sponsor":"University of Pecs","startDate":"2017-12","conditions":"Essential Tremor","enrollment":""},{"nctId":"NCT02025608","phase":"PHASE4","title":"Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome","status":"COMPLETED","sponsor":"Mauro Manconi","startDate":"2013-12","conditions":"Restless Legs Syndrome","enrollment":20},{"nctId":"NCT01976871","phase":"PHASE4","title":"Switching From Oral Dopamine Agonists to Rotigotine","status":"COMPLETED","sponsor":"John Winkelman, MD, PhD","startDate":"2014-08","conditions":"Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease","enrollment":21},{"nctId":"NCT00804479","phase":"","title":"The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2002-01","conditions":"Parkinson's Disease","enrollment":222},{"nctId":"NCT02660060","phase":"NA","title":"Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2015-05","conditions":"Healthy","enrollment":23},{"nctId":"NCT01470859","phase":"NA","title":"The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2011-12","conditions":"Idiopathic Parkinson's Disease","enrollment":30},{"nctId":"NCT02231918","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Restless Legs Syndrome","enrollment":26},{"nctId":"NCT01525641","phase":"","title":"Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Parkinson Disease","enrollment":615},{"nctId":"NCT01052831","phase":"PHASE4","title":"Naltrexone for Impulse Control Disorders in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"Impulse Control Disorder, Parkinson Disease","enrollment":50},{"nctId":"NCT00597896","phase":"PHASE4","title":"Cognitive Enhancement in Bipolar Disorder","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2005-10","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT02347059","phase":"PHASE2","title":"L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-01","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT01511029","phase":"PHASE1","title":"Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":68},{"nctId":"NCT01449578","phase":"PHASE1","title":"Dexpramipexole SAD/MAD Study","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2011-11","conditions":"Amyotrophic Lateral Sclerosis","enrollment":63},{"nctId":"NCT01597310","phase":"PHASE1","title":"Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-05","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01424176","phase":"PHASE1","title":"Dexpramipexole Renal PK Study","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2011-07","conditions":"Amyotrophic Lateral Sclerosis, Renal Insufficiency","enrollment":36},{"nctId":"NCT01607034","phase":"PHASE1","title":"Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-06","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01536249","phase":"PHASE1","title":"Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)","status":"COMPLETED","sponsor":"Knopp Biosciences","startDate":"2012-03","conditions":"Amyotrophic Lateral Sclerosis","enrollment":14},{"nctId":"NCT01191944","phase":"PHASE3","title":"Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Parkinson Disease","enrollment":475},{"nctId":"NCT02264132","phase":"PHASE1","title":"Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT02262546","phase":"PHASE1","title":"Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-05","conditions":"Healthy","enrollment":60},{"nctId":"NCT02261090","phase":"PHASE1","title":"Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-06","conditions":"Healthy","enrollment":14},{"nctId":"NCT02261103","phase":"PHASE1","title":"Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Healthy","enrollment":39},{"nctId":"NCT02260024","phase":"PHASE1","title":"In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT02248181","phase":"","title":"Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-02","conditions":"Parkinson Disease","enrollment":442},{"nctId":"NCT02248168","phase":"","title":"Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-03","conditions":"Parkinson Disease","enrollment":1449},{"nctId":"NCT02248155","phase":"","title":"Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Restless Legs Syndrome","enrollment":2644},{"nctId":"NCT00242008","phase":"PHASE3","title":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00244387","phase":"PHASE3","title":"Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-03","conditions":"Parkinson Disease, Idiopathic","enrollment":506},{"nctId":"NCT02248142","phase":"","title":"Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-02","conditions":"Restless Legs Syndrome","enrollment":1029},{"nctId":"NCT02248220","phase":"","title":"Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-10","conditions":"Parkinson Disease","enrollment":657},{"nctId":"NCT02248207","phase":"","title":"Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Parkinson Disease","enrollment":1293},{"nctId":"NCT02231255","phase":"","title":"Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-02","conditions":"Parkinson Disease","enrollment":1216},{"nctId":"NCT00471588","phase":"PHASE1","title":"Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08","conditions":"Obsessive-Compulsive Disorder","enrollment":52},{"nctId":"NCT02236741","phase":"","title":"The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Heart Failure","enrollment":26814},{"nctId":"NCT02236728","phase":"","title":"Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-02","conditions":"Parkinson Disease","enrollment":497},{"nctId":"NCT02233023","phase":"PHASE4","title":"Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-06","conditions":"Parkinson Disease","enrollment":705},{"nctId":"NCT02231294","phase":"","title":"The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-07","conditions":"Parkinson Disease","enrollment":1464},{"nctId":"NCT02231905","phase":"PHASE4","title":"Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-01","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT01174459","phase":"","title":"Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-08","conditions":"Restless Legs Syndrome","enrollment":571}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":1,"reaction":"ABSCESS DRAINAGE"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"CHOLECYSTITIS ACUTE"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"EPISTAXIS"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HEPATITIS"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"LIVER FUNCTION TEST INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pramipexole (Mirapex)","genericName":"Pramipexole (Mirapex)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramipexole is a dopamine agonist that stimulates D2 and D3 dopamine receptors in the brain to restore dopamine signaling. Used for Parkinson's disease, Restless legs syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}